Error loading player: No playable sources found
Real-world effectiveness of erythropoiesis-stimulating agents after luspatercept in patients with myelodysplastic syndromes: a retrospective analysis of a large healthcare claims database in the United States
Date
April 6, 2024
Explore related products in the following collection:
Abstract: JNCCN23-0560 https://jnccn.org/view/journal...
Speakers
Kashyap Patel, MD
Minnesota Oncology
Derek Tang, PhD, MS, BSPharm
Health Outcomes Research Leader, Bristol-Myers Squibb
Related Products
Reaching Unmet Needs of Lung Cancer Patients Through Hope Totes and Educational Meetings
Abstract: JNCCN23-0752 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pHSR24-173…
Outcome of Positron Emission Tomography –Computed Tomography Staging in Breast Cancer Patients Having Neo-adjuvant Systemic Therapy
Abstract: JNCCN23-0645 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pHSR24-148…
Real-world clinical benefit among patients with lower-risk myelodysplastic syndromes treated with luspatercept
Abstract: JNCCN23-0620 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pHSR24-142…
Prevalence of Anxiety and Depression in Newly-Diagnosed Breast Cancer Patients in Rural Minnesota
Abstract: JNCCN23-0639 https://jnccn.org/view/journal... [https://jnccn.org/view/journals/jnccn/22/2.5/article-pHSR24-145…
